Skip to main content

Oxaliplatin News

Ipsen’s Onivyde Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde (...

Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma

FRIDAY, Sept. 1, 2023 – For patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ)...

Findings of IDEA Collaboration Have Influenced Prescribing Patterns

WEDNESDAY, Aug. 9, 2023 – Changes in prescribing patterns for resected stage III colon cancer have been observed since the abstract presentation of the IDEA collaboration in June 2017, according to...

ASCO: FOLFOX Noninferior to Chemoradiotherapy for Overall Survival in Rectal Cancer

FRIDAY, June 9, 2023 – Neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is noninferior to preoperative chemoradiotherapy with respect to overall survival for patients...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Colorectal Cancer

Oxaliplatin patient information at Drugs.com